A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
266
Enrollment
INDUSTRY
Sponsor class
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
DRUG:
BH-30643
DRUG:
BH-30643
Sponsor
BlossomHill Therapeutics